- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT04855630
Combattre la maladie d'Alzheimer par le sommeil et l'exercice (CASE)
Combattre la maladie d'Alzheimer par le sommeil et l'exercice (CASE)
The Combating Alzheimer's through Sleep and Exercise (CASE) study is an exploratory, hypothesis-generating trial designed to: (1) assess whether improvements in sleep are associated with improvements in cognitive performance and cardiovascular and metabolic health; (2) evaluate the effects of structured, moderate-level aerobic and anaerobic exercise on cognitive performance and cardiovascular and metabolic health; (3) examine the combined, potentially synergistic effects of both interventions on cognitive performance and cardiovascular and metabolic health; and (4) investigate the role of light exposure as a potential modulator of sleep parameters.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Azizi A Seixas, PhD
- Numéro de téléphone: 3052431301
- E-mail: Azizi.seixas@med.miami.edu
Sauvegarde des contacts de l'étude
- Nom: Debbie Chung, PhD
- Numéro de téléphone: 3052431301
- E-mail: dxc1729@miami.edu
Lieux d'étude
-
-
Florida
-
Miami, Florida, États-Unis, 33136
- Recrutement
- University of Miami Hospitals
-
Contact:
- Azizi A Seixas, PhD
- Numéro de téléphone: 3052431301
- E-mail: Azizi.seixas@med.miami.edu
-
Chercheur principal:
- Azizi A Seixas, PhD
-
Sous-enquêteur:
- Alberto Ramos, MD
-
Contact:
- Debbie Chung, PhD
- Numéro de téléphone: 3052431301
- E-mail: dxc1729@miami.edu
-
Sous-enquêteur:
- Debbie Chung, PhD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Aged 55-80 years at the time of the screening visit
- Able to ambulate safely and independently
- Able to safely perform moderate-intensity exercise as per the Physical Activity Readiness Questionnaire (PAR-Q, a validated exercise readiness questionnaire)
- Able to wear and use Fitbit wristwatch and/or the Elemind Neuromodulation headband and Lys devices
- Able to operate a digital device like mobile phone or computer
- Able and willing to provide venous blood samples
- Able to understand and speak English (our AR-based MCI diagnosis tool does not yet have capacity for other languages)
- Able to self-report a history of cognitive changes or impairment
- Be cognitively able (including those with and without MCI) and willing to provide informed consent
- Body weight <400 pounds (<181.4kg) in order to safely operate the NuStep T4r Recumbent Stepper stationary bicycle
Exclusion Criteria:
- Severe mobility limitations that prevent safe participation in moderate exercise protocols
- Unstable or uncontrolled medical conditions (e.g., recent cardiovascular event (<6 months), cerebrovascular accident or transient ischemic attack (<6 months), active cancer, or uncontrolled diabetes) that pose safety concerns
- Inability to complete intake screening procedures
- Severe uncorrected hearing impairment-particularly if it precludes effective utilization of the Elemind Neuromodulation headband-and/or vision impairment that interferes with digital device usage or in-person exercise guidance
- Determined to have Alzheimer's/dementia based on performance on the Quick Mild Cognitive Impairment (QMCI).
- Inability or unwillingness to learn or engage with digital devices (e.g., smartphone, Fitbit, Elemind, or Lys), even with staff support
- Regular pre-study engagement in ≥150 minutes of moderate-level and/or ≥75 minutes of vigorous-level exercise per week based on Fitbit data obtained during the initial seven-day onboarding screening period
- Determined to have sufficient sleep, as defined by a sleep efficiency mean of ≥80%) based on Elemind Neuromodulation headband data obtained during the initial seven-day onboarding screening period
- Current usage of disease-modifying therapy targeting amyloid (e.g., anti-amyloid monoclonal antibodies) or tau
- Body weight ≥400 pounds (≥181.4kg), which would pose a safety risk during the operation of the NuStep recumbent stationary bicycle
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Sleep Only Group
Participants in this group will wear the Elemind headband 3-4 times weekly for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. |
|
Comparateur actif: Exercise Only Group
Participants in this group will participate in a structured, on-site, twice a week exercise program for 60 minutes/session for 8 weeks (16 total sessions). Each exercise session is comprised of 60 minutes, including 10 minutes of warm-up, 20 minutes of cardiovascular exercise on a stationary bike, 20 minutes of resistance training (1 day of upper body focus, 1 day of lower body focus each week), and 10 minutes of cooling off). |
Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
|
Comparateur actif: Exercise and Sleep Group
Participants in this group will take part in the on-site, structured exercise program twice per week for 8 weeks in additional to wearing the Elemind headband 3-4 times per week for 8 weeks. |
The Elemind Neuromodulation headband is a wearable device that utilizes noninvasive, electroencephalography-based (EEG-based) technology to induce a sleep state more rapidly via personalized acoustic stimulation. Specifically, the headband uses a closed-loop system, meaning that the headband conveys stimulation based upon recorded neural activity in order to modulate real-time oscillating circuits at the macroscopic level. This device uses five dry, flexible EEG electrodes-including three recording electrodes that are positioned at the Fpz and Fp1/2 electrode sites in accordance with the 10-20 International System of electrode placement and two silicone rubber-based, linked reference electrodes located at the mastoids-to measure neural activity during sleep and provide an estimation of the phases of real-time neural oscillations. The headband generates a sound pulse by identifying alpha neural oscillations in real-time through endpoint-corrected Hilbert Transform algorithm. Participants randomized to the exercise-only group will engage in an 8-week, home- and site-based exercise intervention designed for older adults across a range of cognitive and physical function levels. All site-based sessions will occur in-person at the study facility under supervision of trained staff. Each week, participants will attend two 60-minute structured exercise sessions, consisting of aerobic training and resistance training. On the remaining five days when subjects will not engage in structured exercise, subjects will be asked to engage in 30 minutes of moderate-intensity walking activities. In-lab exercise protocols will be fully standardized to ensure consistency of exercise dosage and fidelity across participants. The target exercise load will be 270 minutes of moderate-intensity exercise weekly for 8 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Glycated Hemoglobin (HbA1c) Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Total Cholesterol Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Triglycerides Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-sensitivity C-reactive protein (hs-CRP) Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Low-Density Lipoprotein (LDL) Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
C-Peptides
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
High-Density Lipoprotein (HDL) Levels
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
|
Cognitive Function
Délai: Up to 8 weeks
|
Cognitive function gauged from Altoida's Digital Neuro-Signatures |
Up to 8 weeks
|
|
Insulin Levels
Délai: Up to 8 weeks
|
Measured from blood sample |
Up to 8 weeks
|
|
Neurofilament light chain
Délai: Up to Week 8
|
Measured from blood sample |
Up to Week 8
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Total Sleep Duration
Délai: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
Slow Wave Sleep Duration
Délai: Up to Week 8
|
Measured from Elemind |
Up to Week 8
|
|
%Slow-wave Sleep
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Rapid Eye Movement Duration
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%REM
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Light Non-Rapid Eye Movement Duration
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
%Light Non-Rapid Eye Movement Sleep
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Efficiency
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Sleep Onset Latency
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
|
Restlessness (Restless Bouts/Hour during Sleep)
Délai: Up to Week 8
|
Measured by Elemind headband |
Up to Week 8
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Light Exposure
Délai: Up to Week 8
|
Measured by LYS Device |
Up to Week 8
|
|
Psychosocial Metrics
Délai: Up to Week 8
|
Measured by Questionnaires |
Up to Week 8
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Azizi A Seixas, PhD, University of Miami
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 20220931
- 20-01023 (Autre identifiant: NYU)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .